User login
Key clinical point: Eptinezumab led to significantly greater reductions in monthly migraine days (MMD) in patients with migraine who previously failed multiple migraine preventive treatments.
Major finding: Reduction in monthly migraine days over 1-12 weeks was significantly higher with 100 mg eptinezumab (−4.8 days) and 300 mg eptinezumab (−5.3 days) vs placebo (−2.1 days; both P < .0001), with reductions sustained or improved over 13-24 weeks and the odds of achieving ≥50% and ≥75% reduction in MMD favoring eptinezumab over placebo (P < .05).
Study details: This subgroup analysis of the DELIVER trial included 299, 293, and 298 patients with migraine and multiple unsuccessful treatments who were randomly assigned to receive 100 mg eptinezumab, 300 mg eptinezumab, and placebo, respectively.
Disclosures: This study was funded by H. Lundbeck A/S. Some authors declared receiving personal fees or honoraria or serving as consultants or on advisory board for various sources. The other authors declared being full-time employees of H. Lundbeck A/S or one of its subsidiary companies.
Source: Ashina M et al. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: Subgroup analysis of the randomized, placebo-controlled DELIVER study. Cephalalgia. 2023 (Apr 26). doi: 10.1177/03331024231170807
Key clinical point: Eptinezumab led to significantly greater reductions in monthly migraine days (MMD) in patients with migraine who previously failed multiple migraine preventive treatments.
Major finding: Reduction in monthly migraine days over 1-12 weeks was significantly higher with 100 mg eptinezumab (−4.8 days) and 300 mg eptinezumab (−5.3 days) vs placebo (−2.1 days; both P < .0001), with reductions sustained or improved over 13-24 weeks and the odds of achieving ≥50% and ≥75% reduction in MMD favoring eptinezumab over placebo (P < .05).
Study details: This subgroup analysis of the DELIVER trial included 299, 293, and 298 patients with migraine and multiple unsuccessful treatments who were randomly assigned to receive 100 mg eptinezumab, 300 mg eptinezumab, and placebo, respectively.
Disclosures: This study was funded by H. Lundbeck A/S. Some authors declared receiving personal fees or honoraria or serving as consultants or on advisory board for various sources. The other authors declared being full-time employees of H. Lundbeck A/S or one of its subsidiary companies.
Source: Ashina M et al. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: Subgroup analysis of the randomized, placebo-controlled DELIVER study. Cephalalgia. 2023 (Apr 26). doi: 10.1177/03331024231170807
Key clinical point: Eptinezumab led to significantly greater reductions in monthly migraine days (MMD) in patients with migraine who previously failed multiple migraine preventive treatments.
Major finding: Reduction in monthly migraine days over 1-12 weeks was significantly higher with 100 mg eptinezumab (−4.8 days) and 300 mg eptinezumab (−5.3 days) vs placebo (−2.1 days; both P < .0001), with reductions sustained or improved over 13-24 weeks and the odds of achieving ≥50% and ≥75% reduction in MMD favoring eptinezumab over placebo (P < .05).
Study details: This subgroup analysis of the DELIVER trial included 299, 293, and 298 patients with migraine and multiple unsuccessful treatments who were randomly assigned to receive 100 mg eptinezumab, 300 mg eptinezumab, and placebo, respectively.
Disclosures: This study was funded by H. Lundbeck A/S. Some authors declared receiving personal fees or honoraria or serving as consultants or on advisory board for various sources. The other authors declared being full-time employees of H. Lundbeck A/S or one of its subsidiary companies.
Source: Ashina M et al. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: Subgroup analysis of the randomized, placebo-controlled DELIVER study. Cephalalgia. 2023 (Apr 26). doi: 10.1177/03331024231170807